Razzaghi Mohammad Reza, Ghanei Esmat, Malekian Sheida, Mazloomfard Mohammad Mohsen
Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Internal Medicine, Shohada-e-Tajrish Hospital, Tajrish Sq, Tehran, Iran.
J Lasers Med Sci. 2021 Sep 19;12:e49. doi: 10.34172/jlms.2021.49. eCollection 2021.
Although intravascular laser irradiation of blood (ILIB) is deemed an innocuous and useful technique for laser therapy, particularly when systemic effects are required, no study, to our knowledge, has been conducted on the effectiveness and innocuousness of ILIB in treating acute kidney injury (AKI). This study aimed to assess the feasibility and outcomes of ILIB in the management of patients with AKI and comparing them with the Sham-laser group. Twenty-six patients with intra-renal AKI (24-95 years old) at Tajrish Hospitals were evaluated for enrollment eligibility in this clinical trial study. This study was conducted at the nephrology department of Shahid Beheshti University of Medical Science, Tehran, Iran, between 2018 and 2019. Based on the treatment method, the patients' assignment to two groups (ILIB or Sham-laser) was randomly done. Demographic characteristics, need for dialysis, hemoglobin and serum biochemistry changes, serum and urine neutrophil gelatinase-associated lipocalin (NGAL) changes, laser complications, and the hospitalization period were recorded. In terms of the baseline characteristics and biochemistry serum level, no differences were seen between the two groups. All post-treatment parameters, except the hemoglobin value, significantly improved in both groups. Urine NGAL and serum NGAL show declines from the baseline in both groups; however, the reduction slope of these parameters occurred faster in the laser group in a statistically significant manner. A decline in NGAL levels in the laser group during the treatment may suggest that the ILIB can help patients with AKI recover better.
尽管血管内激光照射血液（ILIB）被认为是一种无害且有用的激光治疗技术，特别是在需要全身效应时，但据我们所知，尚未有关于ILIB治疗急性肾损伤（AKI）有效性和无害性的研究。本研究旨在评估ILIB治疗AKI患者的可行性和疗效，并与假激光组进行比较。对塔吉什医院26例肾性AKI患者（年龄24 - 95岁）进行评估，以确定其是否符合本临床试验研究的入组标准。本研究于2018年至2019年在伊朗德黑兰沙希德·贝赫什提医科大学肾脏病科进行。根据治疗方法，将患者随机分为两组（ILIB组或假激光组）。记录人口统计学特征、透析需求、血红蛋白和血清生化变化、血清和尿液中性粒细胞明胶酶相关脂质运载蛋白（NGAL）变化、激光并发症及住院时间。在基线特征和血清生化水平方面，两组未见差异。除血红蛋白值外，两组所有治疗后参数均显著改善。两组尿液NGAL和血清NGAL均较基线下降；然而，激光组这些参数的下降斜率在统计学上显著更快。治疗期间激光组NGAL水平下降可能表明ILIB可帮助AKI患者更好地恢复。
